Pharmacokinetics, disposition and lipid-modulating activity of 5-2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor α agonist in preclinical species and human

Xenobiotica

Volumn 39, Issue 10, 2009, Pages 766-781

  Frederick, K S ^a   Maurer, T S ^a   Kalgutkar, A S ^a   Royer, L J ^a   Francone, O L ^a   Winter, S M ^a   Terra, S G ^a   Chen, D ^a   Gao, X ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome P450; Human; Metabolism; Peroxisome proliferator activated receptor (PPAR ); Pharmacodynamics; Pharmacokinetics; Triglycerides

Indexed keywords

5 [2 [4 (3,4 DIFLUOROPHENOXY)PHENYL] ETHYLSULFAMOYL] 2 METHYLBENZOIC ACID; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; EXPERIMENTAL MONKEY; FEMALE; GLUCURONIDATION; HUMAN; HUMAN CELL; IC 50; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZOIC ACIDS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MICROSOMES, LIVER; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

MACACA FASCICULARIS; MUS; RATTUS;

EID: 70350654020     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903121796     Document Type: Article

References (30)

1. Aleo MD, Lundeen GR, Blackwell DK, Smith WM, Coleman GL, Stadnicki SW, Kluwe WM. (2003). Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist. J Pharmacol Exp Ther 305:1173-1182
2. Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, Webster R, Westgate H. (2008). Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica 38:620-640
3. Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS. (2009. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332-40.
4. Benet LZ, Galeazzi RL. (1971). Noncompartmental determination of the steady-state volume of distribution. J Pharmaceut Sci 68:1071-1074
5. Desai RC, Metzger E, Santini C, Meinke PT, Heck JV, Berger JP, MacNaul KL, Cai TQ, Wright SD, Agarwal A, Moller DE, Sahoo SP. (2006). Design and synthesis of potent and subtype-selective PPAR-alpha agonists. Bioorgan Med Chem Lett 16:1673-1678
6. Desvergne B, Wahli W. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrinol Rev 20:649-688
7. Ding A, Ojingwa JC, McDonagh AF, Burlingame AL, Benet LZ. (1993). Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci USA 90:3797-3801
8. Drexel H. (2007). Nicotinic acid in the treatment of hyperlipidaemia. Fundam Clin Pharmacol 21(Suppl. 2):5-6.
9. Duval C, Muller M, Kersten S. (2007). PPAR-alpha and dyslipidemia. Biochim Biophys Acta 1771:961-971
10. Elsby R, Surry DD, Smith VN, Gray AJ. (2008). Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164
11. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533
12. Issemann I, Green S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
13. Ito K, Houston JB. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceut Res 21:785-792
14. Kalgutkar AS, Soglia JR. (2005). Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
15. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323
16. Nomura M, Tanase T, Ide T, Tsunoda M, Suzuki M, Uchiki H, Murakami K, Miyachi H. (2003). Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor d¢subtype-selective activators. J Med Chem 46:3581-3599
17. Obach RS. (2000). Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95.
18. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. (2008). Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and dose. Chem Res Toxicol 21:1814-1822
19. Pacifici GM, Viani A. (1992). Methods of determining plasma and tissue binding of drugs. Clin Pharmacokinet 23:449-468
20. Rader DJ. (2003). Effects of nonstatin lipid drug therapy on highdensity lipoprotein metabolism. Am J Cardiol 91(Suppl. 7A):18E-23E.
21. Sharma A, Jusko WJ. (2002). Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229-239
22. Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen VL, Nicodeme E, Patel V, PenfornisA, Pineau O, Pohin D, Potvain F, Ruault CB, Saunders M, Toum J, Xu HE, Xu RX, Pianetti PM. (2007). Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPAR-alpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 50:685-695
23. Sprecher DL. (2000). Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 86(Suppl. 12A):46L-50L.
24. Suzuki H, Kneller B, Haining RL, Trager WF, Rettie AE. (2002). (+)-N-3-benzylnirvanol and (-)-N-3-benzyl-phenoparbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Disposit 30:235-239
25. Uetrecht J. (2001). Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Disc Develop 4:55-59
26. Walker GS, Atherton J, Bauman J, Kohl C, Lam W, Reily M, Lou Z, Mutlib A. (2007). Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. Chem Res Toxicol 20:876-886
27. Walsh JS, Reese MJ, Thurmond LM. (2002). The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem-Biol Interact 142:135-154
28. Wang J, Davis M, Li F, Azam F, Scatina J, Talaat R. (2004). A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem Res Toxicol 17:1206-1216
29. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB. (2003). Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278:9869-9874
30. Xu Y, Mayhugh D, Saeed A, Wang X, Thompson RC, Dominianni SJ, Kauffman RF, Singh J, Bean JS, Bensch WR, Barr RJ, Osborne J, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Huang N, Luffer-Atlas D, Rungta D, Maise DE, Mantlo NB. (2003). Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor d¢ agonist. J Med Chem 46:5121-5124